UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB


[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

         For quarterly period ended:  September 30, 2002

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


        NEVADA                                             87-0458170
(State of incorporation)            (I.  R.  S.  Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

As of October 22, 2002, the issuer had a total of 708,000 shares of common
stock issued and outstanding.

Transitional small business disclosure format:  Yes [ ]  No [X]

<PAGE>

                        TABLE OF CONTENTS

                  PART I: FINANCIAL INFORMATION

Item 1:  Financial Statements..............................................3

Item 2:  Plan of Operations ...............................................8

Item 3:  Controls and Procedures...........................................9

                    PART II: OTHER INFORMATION

Item 6:  Exhibits and Reports on Form 8-K..................................9

Signatures and Certifications .............................................9







                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

     The financial information set forth below with respect to our statements
of operations for the three and nine month periods ended September 30, 2002
and 2001 is unaudited.  This financial information, in the opinion of
management, includes all adjustments consisting of normal recurring entries
necessary for the fair presentation of such data.  The results of operations
for the three and nine months ended September 30, 2002, are not necessarily
indicative of results to be expected for any subsequent period.







                                2
<PAGE>





                 Skinovation Pharmaceutical, Inc.
                       Financial Statements
                        September 30, 2002



<PAGE>   3





                 Skinovation Pharmaceutical, Inc.
                   (A Development Stage Company)
                          Balance Sheets



                              ASSETS


                                                    Sept. 30,    December 31,
                                                      2002          2001
                                                 -------------- -------------
                                                  (Unaudited)

CURRENT ASSETS                                   $           -  $          -
                                                 -------------- -------------

  TOTAL ASSETS                                   $           -  $          -
                                                 ============== =============



               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                 $      28,776  $     28,776
                                                 -------------- -------------

  Total Liabilities                                     28,776        28,776
                                                 -------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares issued
  and outstanding                                          708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (54,632)      (54,632)
                                                 -------------- -------------

  Total Stockholders' Equity                           (28,776)      (28,776)
                                                 -------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY     $           -  $          -
                                                 ============== =============

<PAGE> 4




                 Skinovation Pharmaceutical, Inc.
                   (Development Stage Company)
                     Statement of Operations
                           (Unaudited)


<TABLE>
<CAPTION>



                           For the        For the        For the        For the        From
                           three months   three months   nine months    nine months    inception on
                           ended Sept.30, ended Sept.30, ended Sept.30, ended Sept.30, January 15, 1988
                           2002           2001           2002           2001           to Sept.30, 2002
                           -------------- -------------- -------------- -------------- ----------------

                        <c>            <c>            <c>            <c>            <c>
REVENUES                   $           -  $           -  $           -  $           -  $      27,937
                           -------------- -------------- -------------- -------------- --------------
EXPENSES

  General & Administrative             -              -              -              -        119,644
                           -------------- -------------- -------------- -------------- --------------

    TOTAL EXPENSES                     -              -              -              -        119,644
                           -------------- -------------- -------------- -------------- --------------
NET LOSS BEFORE
 DISCONTINUED OPERATIONS               -              -              -              -        (91,707)

GAIN ON DISPOSAL OF
 OPERATIONS                            -              -              -              -         37,075
                           -------------- -------------- -------------- -------------- --------------

NET INCOME (LOSS)          $           -  $           -  $           -  $           -  $     (54,632)
                           ============== ============== ============== ============== ==============

NET LOSS PER SHARE         $           -  $           -  $           -  $           -  $       (0.12)
                           ============== ============== ============== ============== ==============

WEIGHTED AVERAGE SHARES
  OUTSTANDING                    708,000        708,000        708,000        708,000        533,610
                           ============== ============== ============== ============== ==============


</TABLE>
<PAGE>
<TABLE>
<CAPTION>



                        Skinovation Pharmaceutical, Inc.
                          (A Development Stage Company)
                             Statement of Cash Flows
                                   (Unaudited)

                                                                                    From
                                                                                    Inception on
                                                         For the nine months ended  January 15, 1988
                                                                Sept. 30            Through
                                                            2002           2001     Sept. 30, 2002
                                                        ------------- ------------- --------------
<S>                                                     <C>           <C>           <C>
Cash Flows from Operating Activities

  Net Loss                                              $          -  $          -  $     (54,632)
  Less  Non-cash Items:
   Shares issued for services                                      -             -         10,433
   Shares issued for debt payment                                  -             -          1,424
   Increase in accounts payable                                    -             -         28,776
   Loss on disposal of PP&E                                        -             -          5,263
                                                        ------------- ------------- --------------

  Net Cash Provided (Used) by Operating Activities                 -             -         (8,736)
                                                        ------------- ------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                               -             -         (5,264)
                                                        ------------- ------------- --------------

  Net Cash Provided (Used) by Investing Activities                 -             -         (5,264)
                                                        ------------- ------------- --------------
Cash Flows from Financing Activities

  Cash paid for offering costs                                     -             -         (7,000)
  Common stock issued for cash                                     -             -         21,000
                                                        ------------- ------------- --------------

  Net Cash Provided (Used) by Financing Activities                 -             -         14,000
                                                        ------------- ------------- --------------

Increase (Decrease) in Cash                                        -             -              -

Cash and Cash Equivalents at Beginning of Period                   -             -              -
                                                        ------------- ------------- --------------

Cash and Cash Equivalents at End of Period              $          -  $          -  $           -
                                                        ============= ============= ==============

Supplemental Cash Flow Information:

  Stock issued for debt payment                         $          -  $          -  $       1,424
  Stock issued for services                             $          -  $          -  $      10,433
  Cash Paid For:
    Interest                                            $          -  $          -  $           -
    Income Taxes                                        $          -  $          -  $           -



</TABLE>
<PAGE> 6

                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                Notes to the Financial Statements
                        September 30, 2002


GENERAL
-------

Skinovation Pharmaceutical, Inc.  (the Company) has elected to omit
substantially all footnotes to the financial statements for the nine months
ended September 30, 2002 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2001.

UNAUDITED INFORMATION
---------------------

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.











<PAGE> 7


     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements and any
statements contained in this Form 10-QSB that are not statements of historical
fact may be deemed to be forward-looking statements.  Without limiting the
foregoing, words such as "may," "will," "expect," "believe," "anticipate,"
"estimate" or "continue" or comparable terminology are intended to identify
forward-looking statements.  These statements by their nature involve
substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within Skinovation's
control.  These factors include, but are not limited to, economic conditions
generally, failure by management to successfully develop business
relationships, competition within the merger and acquisitions market, lack of
operations and future changes by regulatory agencies.


ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the nine month period ended September 30, 2002, we had no
cash on hand and total current liabilities of $28,776.  The $28,766 account
payable is related to accounting and legal fees paid on our behalf by a
related party in fiscal year 1999.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.

     Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Skinovation. In addition, we
have not made a formal study of the economic potential of any business.  At
the date of this filing, we have not identified any assets or business
opportunities for acquisition.

     All risks inherent in new and inexperienced enterprises are inherent in
our business.  Potential investors must recognize that because of our limited
capital available for investigation and management's limited experience in
business analysis we may not discover or adequately evaluate adverse facts
about the business opportunity to be acquired.  Also, we intend to concentrate
our acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.


                                8
<PAGE>


ITEM 3: CONTROLS AND PROCEDURES

     As a result of new SEC regulations, our Board formalized the disclosure
controls and procedures we use to ensure that material information regarding
our company and its operations is provided to the public in a timely manner.
On October 28, 2002, our President, acting in the capacity of principal
executive and financial officer, evaluated the effectiveness of these
disclosure controls and procedures and determined that there were no
significant deficiencies in these procedures.

     Also, the President did not identify any deficiencies or material
weaknesses in our internal controls, nor did he identify fraud that involved
our management who had a significant role in our internal controls.  He did
not find any deficiencies of weaknesses which would require changes to be made
or corrective actions to be taken related to our internal controls.


                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)      Part II Exhibits

3.1      Articles of Incorporation as amended  (Incorporated by reference to
         exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)

3.2      Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of
         the Form-SB, filed July 11, 2000)


(b)      Reports on Form 8-K

         None.



                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                              Skinovation Pharmaceutical Incorporated


       10/28/02                     /s/ John W. Peters
Date_______________           By: ____________________________________
                                  John W. Peters
                                  President, Principal Financial Officer, and
                                  Director



                                9
<PAGE>


            PRINCIPAL EXECUTIVE OFFICER CERTIFICATION

I, John W. Peters, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Skinovation
Pharmaceutical Incorporated;

2.   Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



          10/28/02            /S/ John W. Peters
Date: ________________      ___________________________________________
                            John W. Peters, Principal Executive Officer



                                10
<PAGE>

            PRINCIPAL FINANCIAL OFFICER CERTIFICATION

I, John W. Peters, certify that:

1.   I have reviewed this quarterly report on Form 10-QSB of Skinovation
Pharmaceutical Incorporated;

2.   Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statement made, in light of the circumstances under which statements
were made, not misleading with respect to the period covered by this quarterly
report;

3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report.

4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a)   designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;

b)   evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5.   The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):

a)   all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and

b)   any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and

6.   The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


         10/28/02               /S/ John W. Peters
Date: ______________          ___________________________________________
                              John W. Peters, Principal Financial Officer





                    11